We use cookies for a better user experience. Read our Privacy Policy

I Agree

Dry Eye Disease Market

Dry Eye Disease Market (Product - Artificial Tears, Anti-inflammatory (Cyclosporine, Corticosteroid, and Lifitegrast), Punctal Plugs, and Secretagogue; Distribution Channel - Hospital Pharmacies, Independent Pharmacies & Drug Stores, and Online pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017 - 2025

Global Dry Eye Disease Market: Snapshot

Dry eye disease is a common phenomenon which is likely to be experienced by an individual in his/her lifetime. Dry eye disease is a multifactorial disease which is characterized by insufficiency of tears in eye. Insufficient lubrication in eye lead to burning, sensing, redness and pain in eye. Dry eye disease is categorized into evaporative dry eye disease and aqueous deficiency dry eye diseases. Aqueous deficiency dry eye disease is mostly caused by Meibomian Gland Dysfunction (MGD), where in tear producing glands are insufficient to produce the tears. Dry eye disease is treated by various methods such as medications, medical device therapies and surgical interventions.

According to various studies conducted across the globe, the prevalence of dry eye disease is estimated to be in the range of 8% to 34%. There are various associated risk factors for dry eye disease such as ageing, diabetes, refractive surgeries such as LASIK, consumption of certain medications and environmental factors such as pollution. Rise in geriatric population across the globe is estimated to surge number of patients with dry eye disease. Key players are investing on development of new treatments for dry eye disease which is projected to drive expansion of the global market. However, many of the patients and physicians rely on over the counter available artificial tears for treatment of dry eye disease in initial stage. There are few prescription medications indicated for dry eye disease treatment which are comparatively expensive. Moreover these medications work on signs and symptoms of dry eye and doesn’t treat root cause of dry eye disease.    

Transparency Market Research estimates that the dry eye disease market will expand at a CAGR of 4.5% over the forecast period between 2017 and 2025. Escalating at this pace, the market, which had a valuation of US$ 5,045.2 Mn in 2016 in terms of revenue, is projected to rise to US$ 7,780.0 Mn by 2025.

gobal dry eye disease market

Demand for Anti-inflammatory Drugs to Remain High Through Forecast Period

The dry eye disease market has been segmented on the basis of product, distribution channel and geography. On the basis of product, anti-inflammatory drugs segment is projected to lead the market in terms of revenue and continues to dominate the market during the forecast period followed by artificial tears segment. Introduction of new anti-inflammatory drug such as Lifitegrast (Xiidra) and advancements in the existing cyclosporine eye drops is estimated to propel expansion of the segment. On the basis of distribution channel, the market is segmented into hospital pharmacies, independent pharmacies & drug stores and online pharmacies.

Rising Approval of Novel Drugs Pushes North America to Market’s fore

Geographically, dry eye disease market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America dominated the global dry eye disease market in terms of revenue in 2016 and is projected to retain its dominant position during the forecast period from 2017 to 2025. High adoption of prescription dry eye disease drugs in the U.S. and increasing number of approvals for new drugs and devices from the U.S. FDA are some of the major factors responsible for high share held by North America in 2016. Asia Pacific is anticipated to gain market share during the forecast period owing to large patient pool, increasing per capita health care expenditure and increasing investment of key players in this market.

Key companies profiled in the report include Santen Pharmaceutical Co., Ltd., Novartis AG, Valeant Pharmaceuticals International, Inc., Allergan plc, Shire plc, TRB Chemedica International SA, Sun Pharmaceutical Industries Ltd., Senju Pharmaceutical Co., Ltd., Sentiss Pharma Pvt. Ltd., Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd., Mitotech S.A. and  FCI S.A.S.

Increasing Awareness and the Booming Geriatric Population to Accelerate the Growth of the Dry Eye Disease Market

With the rise in the geriatric population and the increasing number of eye-related disorders among them, the dry eye disease market is estimated to gain good growth prospects through the assessment period of 2017-2025. The growing prevalence of these diseases has urged many researchers and developers to discover good treatment options, which has eventually accelerated the growth prospects of the dry eye disease market.

  • Dry eye disease, also known as keratoconjunctivitis sicca (KCS) is a condition in which the tears present in an individual are not able to provide the right lubrication to the eyes. This tear instability can lead to inflammation and can also damage the eye surface. The growing emergence of novel treatments on the back of the intense research and development activities may bring tremendous growth opportunities for the dry eye disease market.
  • The increasing awareness about dry eye disease among a large number of individuals through various government and non-government initiatives will prove to be a prominent growth booster for the dry eye disease market. Furthermore, quick approvals for novel treatment measures from regulatory authorities will also bring good growth prospects for the dry eye disease market.
  • Strategic collaborations form an important part of the dry eye disease market. The players in the dry eye disease market are always involved in these activities for strengthening their hold. These activities eventually help in increasing the growth rate of the dry eye disease market.
  • The novel coronavirus pandemic has impacted the dry eye disease market to a considerable extent. The disruptions observed across the globe in terms of supply chain and logistics due to the lockdown restrictions have dented the growth prospects substantially. However, as the healthcare industry was exempted from the restrictions, the dry eye disease market was not affected much.

The global dry eye disease market has been segmented as follows:           

Product

  • Artificial Tears
  • Anti-inflammatory Drugs
  • Cyclosporine
  • Corticosteroids
  • Lifitegrast
  • Punctal Plugs
  • Secretagogue
  • Others

Distribution Channel

  • Hospital Pharmacies
  • Independent Pharmacies & Drug Stores
  • Online Pharmacies

Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Rest of MEA
Dry Eye Disease Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Dye Eye Disease Market

4. Market Overview
     4.1. Introduction
            4.1.2. Industry Evolution / Developments
     4.2. Overview
     4.3. Market Dynamics
            4.3.1. Drivers
                     4.3.1.1. High prevalence and rise in incidence rates of dry eye disease and associated risk factors
                     4.3.1.2. Technical advancements and promising pipeline products
                     4.3.1.3. Novel dry eye diagnostic tools in offering
                     4.3.1.4. Growing number of eye care centers prompting surge in product utilization
            4.3.2. Restraints
                     4.3.2.1. High cost of specialty dry eye products with Unclear Reimbursement Scenario
                     4.3.2.2. Alternative therapies in offering
            4.3.3. Opportunities
                     4.3.3.1. Development of novel treatments
     4.4. Global Dye Eye Disease Market Analysis and Forecasts, 2015–2025
            4.4.1. Market Revenue Projections (US$ Mn)
     4.5. Porter’s Five Force Analysis
     4.6. Market Outlook
     4.7.Global Prevalence of Dry Eye Disease
     4.8.Pipeline Analysis : Dry Eye Disease Drugs
     4.9.Autologous Serum Tears – Overview
     4.10.Key Industry Trends

5. Global Dye Eye Disease Market Analysis and Forecasts, By Product 
     5.1. Introduction & Definition
     5.2. Key Findings / Developments
     5.3. Key Trends
     5.4. Market value Forecast By Product, 2015–2025
            5.4.1. Artificial Tears
            5.4.2. Anti-inflammatory
                     5.4.2.1. Cyclosporine 
                     5.4.2.2. Corticosteroid
                     5.4.2.3. Lifitegrast
            5.4.3. Punctal Plugs
            5.4.4. Secretagogue
            5.4.5. Others
     5.5. Market Attractiveness By Product 

6. Global Dye Eye Disease Market Analysis and Forecasts, By Distribution Channel 
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Key Trends
     6.4. Market value Forecast By Distribution Channel, 2015–2025
            6.4.1. Hospital Pharmacies
            6.4.2. Independent Pharmacies & Drug Stores
            6.4.3. Online Pharmacies
     6.5. Market Attractiveness By Distribution Channel 

7. Global Dye Eye Disease Market Analysis and Forecasts, By Region
     7.1. Key Findings
     7.2. Market value Forecast By Region
            7.2.1. North America 
            7.2.2. Europe 
            7.2.3. Asia Pacific 
            7.2.4. Latin America 
            7.2.5. Middle East & Africa 
     7.3. Market Attractiveness By Region
     7.4. Key Trends, By Region

8. North America Dye Eye Disease Market Analysis and Forecast
     8.1. Key Findings
     8.2. Market value Forecast By Product, 2015–2025
            8.2.1. Artificial Tears
            8.2.2. Anti-inflammatory
                     8.2.2.1. Cyclosporine 
                     8.2.2.2. Corticosteroid
                     8.2.2.3. Lifitegrast
            8.2.3. Punctal Plugs
            8.2.4. Secretagogue
            8.2.5. Others
     8.3. Market value Forecast By Distribution Channel, 2015–2025
            8.3.1. Hospital Pharmacies
            8.3.2. Independent Pharmacies & Drug Stores
            8.3.3. Online Pharmacies
     8.4. Market value Forecast By Country, 2015–2025
            8.4.1. US
            8.4.2. Canada
     8.5. Market Attractiveness Analysis 
            8.5.1. By Product 
            8.5.2. By Distribution Channel 
            8.5.3. By Country

9. Europe Dye Eye Disease Market Analysis and Forecast
     9.1. Key Findings
     9.2. Market value Forecast By Product, 2015–2025
            9.2.1. Artificial Tears
            9.2.2. Anti-inflammatory
                     9.2.2.1. Cyclosporine 
                     9.2.2.2. Corticosteroid
                     9.2.2.3. Lifitegrast
            9.2.3. Punctal Plugs
            9.2.4. Secretagogue
            9.2.5. Others
     9.3. Market value Forecast By Distribution Channel, 2015–2025
            9.3.1. Hospital Pharmacies
            9.3.2. Independent Pharmacies & Drug Stores
            9.3.3. Online Pharmacies
     9.4. Market value Forecast By Country / Sub-region, 2015–2025
            9.4.1. Germany
            9.4.2. UK
            9.4.3. France
            9.4.4. Italy
            9.4.5. Spain
            9.4.6. Rest of Europe
     9.5. Market Attractiveness Analysis 
            9.5.1. By Product 
            9.5.2. By Distribution Channel 
            9.5.3. By Country / Sub-region

10. Asia Pacific Dye Eye Disease Market Analysis and Forecast
     10.1.Key Findings
     10.2.Market value Forecast By Product, 2015–2025
            10.2.1. Artificial Tears
            10.2.2. Anti-inflammatory
                     10.2.2.1. Cyclosporine 
                     10.2.2.2. Corticosteroid
                     10.2.2.3. Lifitegrast
            10.2.3. Punctal Plugs
            10.2.4. Secretagogue
            10.2.5. Others
     10.3.Market value Forecast By Distribution Channel, 2015–2025
            10.3.1. Hospital Pharmacies
            10.3.2. Independent Pharmacies & Drug Stores
            10.3.3. Online Pharmacies
     10.4.Market value Forecast By Country / Sub-region, 2015–2025
            10.4.1. China
            10.4.2. Japan
            10.4.3. India
            10.4.4. Australia and New Zealand
            10.4.5. Rest of APAC
     10.5.Market Attractiveness Analysis 
            10.5.1. By Product 
            10.5.2. By Distribution Channel 
            10.5.3. By Country / Sub-region

11. Latin America Dye Eye Disease Market Analysis and Forecast
     11.1.Key Findings
     11.2.Market value Forecast By Product, 2015–2025
            11.2.1. Artificial Tears
            11.2.2. Anti-inflammatory
                     11.2.2.1. Cyclosporine 
                     11.2.2.2. Corticosteroid
                     11.2.2.3. Lifitegrast
            11.2.3.Punctal Plugs
            11.2.4. Secretagogue
            11.2.5. Others
     11.3.Market value Forecast By Distribution Channel, 2015–2025
            11.3.1. Hospital Pharmacies
            11.3.2. Independent Pharmacies & Drug Stores
            11.3.3. Online Pharmacies
     11.4.Market value Forecast By Country / Sub-region, 2015–2025
            11.4.1. Brazil
            11.4.2. Mexico
            11.4.3. Rest of LATAM
     11.5.Market Attractiveness Analysis 
            11.5.1. By Product 
            11.5.2. By Distribution Channel 
            11.5.3. By Country / Sub-region

12. Middle East & Africa Dye Eye Disease Market Analysis and Forecast
     12.1.Key Findings
     12.2.Market value Forecast By Product, 2015–2025
            12.2.1. Artificial Tears
            12.2.2. Anti-inflammatory
                     12.2.2.1. Cyclosporine 
                     12.2.2.2. Corticosteroid
                     12.2.2.3. Lifitegrast
            12.2.3. Punctal Plugs
            12.2.4. Secretagogue
            12.2.5. Others
     12.3.Market value Forecast By Distribution Channel, 2015–2025
            12.3.1. Hospital Pharmacies
            12.3.2. Independent Pharmacies & Drug Stores
            12.3.3. Online Pharmacies
     12.4.Market value Forecast By Country / Sub-region, 2015–2025
            12.4.1. GCC Countries
            12.4.2. South Africa
            12.4.3. Israel
            12.4.4. Rest of MEA
     12.5.Market Attractiveness Analysis 
            12.5.1. By Product 
            12.5.2. By Distribution Channel 
            12.5.3. By Country / Sub-region

13. Competition Landscape
     13.1.Market Player – Competition Matrix (By Tier and Size of companies)
     13.2.Market Share Analysis By Company (2016)
     13.3.Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
            13.3.1. Santen Pharmaceutical Co., Ltd.
                     13.3.1.1. Company Overview
                     13.3.1.2. Business Overview
                     13.3.1.3. Product Overview
                     13.3.1.4. Financial Overview
                     13.3.1.5. Strategic Overview
                     13.3.1.6. SWOT Analysis
            13.3.2. Novartis AG
                     13.3.2.1. Company Overview
                     13.3.2.2. Business Overview
                     13.3.2.3. Product Overview
                     13.3.2.4. Financial Overview
                     13.3.2.5. Strategic Overview
                     13.3.2.6. SWOT Analysis 
            13.3.3. Valeant Pharmaceuticals International, Inc. 
                     13.3.3.1. Company Overview
                     13.3.3.2. Business Overview
                     13.3.3.3. Product Overview
                     13.3.3.4. Financial Overview
                     13.3.3.5. Strategic Overview
                     13.3.3.6. SWOT Analysis
            13.3.4. Allergan plc 
                     13.3.4.1. Company Overview
                     13.3.4.2. Business Overview
                     13.3.4.3. Product Overview
                     13.3.4.4. Financial Overview
                     13.3.4.5. Strategic Overview
                     13.3.4.6. SWOT Analysis
            13.3.5. Shire plc 
                     13.3.5.1. Company Overview
                     13.3.5.2. Business Overview
                     13.3.5.3. Product Overview
                     13.3.5.4. Financial Overview
                     13.3.5.5. Strategic Overview
                     13.3.5.6. SWOT Analysis
            13.3.6. TRB Chemedica International SA 
                     13.3.6.1. Company Overview
                     13.3.6.2. Business Overview
                     13.3.6.3. Product Overview
                     13.3.6.4. Strategic Overview
                     13.3.6.5. SWOT Analysis
            13.3.7. Sun Pharmaceutical Industries Ltd. 
                     13.3.7.1. Company Overview
                     13.3.7.2. Business Overview
                     13.3.7.3. Product Overview
                     13.3.7.4. Financial Overview
                     13.3.7.5. Strategic Overview
                     13.3.7.6. SWOT Analysis
            13.3.8. Senju Pharmaceutical Co., Ltd. 
                     13.3.8.1. Company Overview
                     13.3.8.2. Business Overview
                     13.3.8.3. Product Overview
                     13.3.8.4. Financial Overview
                     13.3.8.5. Strategic Overview
                     13.3.8.6. SWOT Analysis
            13.3.9. Sentiss Pharma Pvt. Ltd. 
                     13.3.9.1. Company Overview
                     13.3.9.2. Business Overview
                     13.3.9.3. Product Overview
                     13.3.9.4. Strategic Overview
\                     13.3.9.5. SWOT Analysis
            13.3.10. Johnson & Johnson 
                     13.3.10.1. Company Overview
                     13.3.10.2. Business Overview
                     13.3.10.3. Product Overview
                     13.3.10.4. Financial Overview
                     13.3.10.5. Strategic Overview
                     13.3.10.6. SWOT Analysis
            13.3.11. Otsuka Pharmaceutical Co., Ltd. 
                     13.3.11.1. Company Overview
                     13.3.11.2. Business Overview
                     13.3.11.3. Product Overview
                     13.3.11.4. Financial Overview
                     13.3.11.5. Strategic Overview
                     13.3.11.6. SWOT Analysis
            13.3.12. Mitotech S.A. 
                     13.3.12.1. Company Overview
                     13.3.12.2. Business Overview
                     13.3.12.3. Product Overview
                     13.3.12.4. Strategic Overview
                     13.3.12.5. SWOT Analysis
            13.3.13. FCI S.A.S. 
                     13.3.13.1. Company Overview
                     13.3.13.2. Business Overview
                     13.3.13.3. Product Overview
                     13.3.13.4. Strategic Overview
                     13.3.13.5. SWOT Analysis

List of Tables 

Table 01: Pipeline Analysis (1/5)
Table 02: Pipeline Analysis (2/5)
Table 03: Pipeline Analysis (3/5)
Table 04: Pipeline Analysis (4/5)
Table 05: Pipeline Analysis (5/5)
Table 06: Global Dry Eye Disease Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
Table 07: Global Dry Eye Disease Market Volume (Number of Units) Forecast, by Anti-inflammatory Drugs, 2015–2025
Table 08: Global Dry Eye Disease Market Size (US$ Mn) Forecast, by Distribution channel, 2015–2025
Table 09: Global Dry Eye Disease Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 10: North America Dry Eye Disease Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
Table 11: North America Dry Eye Disease Market Volume (Number of Units) Forecast, by Anti-inflammatory Drugs, 2015–2025
Table 12: North America Dry Eye Disease Market Value (US$ Mn) Forecast, by Distribution channel, 2015–2025
Table 13: North America Dry Eye Disease Market Value (US$ Mn) Forecast, by Country, 2015–2025
Table 14: Europe Dry Eye Disease Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
Table 15: Europe Dry Eye Disease Market Volume (Number of Units) Forecast, by Anti-inflammatory Drugs, 2015–2025
Table 16: Europe Dry Eye Disease Market Value (US$ Mn) Forecast, by Distribution channel, 2015–2025
Table 17: Europe Dry Eye Disease Market Value (US$ Mn) Forecast, by Country / Sub-region, 2015–2025
Table 18: Asia Pacific Dry Eye Disease Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
Table 19: Asia Pacific Dry Eye Disease Market Volume (Number of Units) Forecast, by Anti-inflammatory Drugs, 2015–2025
Table 20: Asia Pacific Dry Eye Disease Market Value (US$ Mn) Forecast, by Distribution channel, 2015–2025
Table 21: Asia Pacific Dry Eye Disease Market Value (US$ Mn) Forecast, by Country / Sub-region, 2015–2025
Table 22: Latin America Dry Eye Disease Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
Table 23: Latin America Dry Eye Disease Market Volume (Number of Units) Forecast, by Anti-inflammatory Drugs, 2015–2025
Table 24: Latin America Dry Eye Disease Market Value (US$ Mn) Forecast, by Distribution channel, 2015–2025
Table 25: Latin America Dry Eye Disease Market Value (US$ Mn) Forecast, by Country / Sub-region, 2015–2025
Table 26: Middle East & Africa Dry Eye Disease Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
Table 27: Middle East & Africa Dry Eye Disease Market Volume (Number of Units) Forecast, by Anti-inflammatory Drugs, 2015–2025
Table 28: Middle East & Africa Dry Eye Disease Market Value (US$ Mn) Forecast, by Distribution channel, 2015–2025
Table 29: Middle East & Africa Dry Eye Disease Market Value (US$ Mn) Forecast, by Country / Sub-region, 2015–2025

List of Figures

Figure 01: Dry Eye Disease Market Size (US$ Mn), by Product Type, 2016 (A)
Figure 02: Dry Eye Disease Market Revenue (%), by Distribution channel, 2016 (A)
Figure 03: Global Dry Eye Disease Market Revenue (%), by Region, 2016 (A)
Figure 04: Product Type Revenue (%), 2016
Figure 05: Distribution Channel Revenue  (%), 2016
Figure 06: Global Dry Eye Disease Market Size (US$ Mn) Forecast, 2015–2025
Figure 07: Market Value Share, by Product Type (2016)
Figure 08: Market Value Share, by Distribution Channel (2016)
Figure 09: Market Value Share, by Region (2016)
Figure 10: Global Prevalence Dry eye Disease
Figure 11: Global Dry Eye Disease Market Value Share, by Product Type, 2016 and 2025
Figure 12: Global Dry Eye Disease Market Attractiveness, by Product Type, 2017–2025
Figure 13: Global Dry Eye Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Artificial Tears, 2015–2025
Figure 14: Global Dry Eye Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Anti-inflammatory Drugs, 2015–2025
Figure 15: Global Dry Eye Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Punctal Plugs, 2015–2025
Figure 16: Global Dry Eye Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Secretagogue, 2015–2025
Figure 17: Global Dry Eye Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2015–2025
Figure 18: Global Dry Eye Disease Market Value Share, by Distribution channel, 2016 and 2025
Figure 19: Global Dry Eye Disease Market Attractiveness, by Distribution channel, 2017–2025
Figure 20: Global Dry Eye Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2015–2025
Figure 21: Global Dry Eye Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Independent Pharmacies & Drug Stores, 2015–2025
Figure 22: Global Dry Eye Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2015–2025
Figure 23: Global Market Scenario
Figure 24: Global Dry Eye Disease Market Value Share, by Region, 2016 and 2025 
Figure 25: Global Dry Eye Disease Market Attractiveness, by Region, 2017–2025
Figure 26: North America Dry Eye Disease Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
Figure 27: North America Dry Eye Disease Market Value Share Analysis, by Product Type, 2016 and 2025
Figure 28: North America Dry Eye Disease Market Value Share Analysis, by Distribution channel, 2016 and 2025
Figure 29: North America Dry Eye Disease Market Value Share Analysis, by Country, 2016 and 2025
Figure 30: North America Dry Eye Disease Market Attractiveness Analysis, by Country
Figure 31: North America Dry Eye Disease Market Attractiveness Analysis, by Product Type
Figure 32: North America Dry Eye Disease Market Attractiveness Analysis, by Distribution Channel
Figure 33: Europe Dry Eye Disease Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
Figure 34: Europe Dry Eye Disease Market Value Share Analysis, by Product Type, 2016 and 2025
Figure 35: Europe Dry Eye Disease Market Value Share Analysis, by Distribution channel, 2016 and 2025
Figure 36: Europe Dry Eye Disease Market Value Share Analysis, by Country / Sub-region, 2016 and 2025
Figure 37: Europe Dry Eye Disease Market Attractiveness Analysis, by Country  / Sub-region
Figure 38: Europe Dry Eye Disease Market Attractiveness Analysis, by Product Type
Figure 39: Europe Dry Eye Disease Market Attractiveness Analysis, by Distribution Channel
Figure 40: Asia Pacific Dry Eye Disease Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
Figure 41: Asia Pacific Dry Eye Disease Market Value Share Analysis, by Product Type, 2016 and 2025
Figure 42: Asia Pacific Dry Eye Disease Market Value Share Analysis, by Distribution channel, 2016 and 2025
Figure 43: Asia Pacific Dry Eye Disease Market Value Share Analysis, by Country  / Sub-region, 2016 and 2025
Figure 44: Asia Pacific Dry Eye Disease Market Attractiveness Analysis, by Country  / Sub-region
Figure 45: Asia Pacific Dry Eye Disease Market Attractiveness Analysis, by Product Type
Figure 46: Asia Pacific Dry Eye Disease Market Attractiveness Analysis, by Distribution Channel
Figure 47: Latin America Dry Eye Disease Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
Figure 48: Latin America Dry Eye Disease Market Value Share Analysis, by Product Type, 2016 and 2025
Figure 49: Latin America Dry Eye Disease Market Value Share Analysis, by Distribution channel, 2016 and 2025
Figure 50: Latin America Dry Eye Disease Market Value Share Analysis, by Country / Sub-region, 2016 and 2025
Figure 51: Latin America Dry Eye Disease Market Attractiveness Analysis, by Country / Sub-region
Figure 52: Latin America Dry Eye Disease Market Attractiveness Analysis, by Product Type
Figure 53: Latin America Dry Eye Disease Market Attractiveness Analysis, by Distribution Channel
Figure 54: Middle East & Africa Dry Eye Disease Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
Figure 55: Middle East & Africa Dry Eye Disease Market Value Share Analysis, by Product Type, 2016 and 2025
Figure 56: Middle East & Africa Dry Eye Disease Market Value Share Analysis, by Distribution channel, 2016 and 2025
Figure 57: Middle East & Africa Dry Eye Disease Market Value Share Analysis, by Country / Sub-region, 2016 and 2025
Figure 58: Middle East & Africa Dry Eye Disease Market Attractiveness Analysis, by Country  / Sub-region
Figure 59: Middle East & Africa Dry Eye Disease Market Attractiveness Analysis, by Product Type
Figure 60: Middle East & Africa Dry Eye Disease Market Attractiveness Analysis, by Distribution Channel
Figure 61: Global Dry Eye Disease Market Share Analysis, by Company (2016)
Figure 62: Santen Pharmaceutical Co., Ltd. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 63: Santen Pharmaceutical Co., Ltd. R&D Expenditure (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 64: Santen Pharmaceutical Co., Ltd. Breakdown of Net Sales, By Business Segment, 2016
Figure 65: Novartis AG.  Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 66: Novartis AG. R&D Expenditure (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 67: Novartis AG. Breakdown of Net Sales, By Region, 2016
Figure 68: Valeant Pharmaceuticals International, Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 69: Valeant Pharmaceuticals International, Inc. R&D Expenditure (US$ Mn) & Y-o-Y Growth (%), 2014–2016
Figure 70: Valeant Pharmaceuticals International, Inc. Breakdown of Net Sales, By Business Segment, 2016
Figure 71: Allergan plc  Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 72: Allergan plc R&D Expenditure (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 73: Allergan plc Breakdown of Net Sales, By Business Segment, 2016
Figure 74: Shire plc Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 75: Shire plc R&D Expenditure (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 76: Shire plc Breakdown of Net Sales, By Business Segment, 2016
Figure 77: Sun Pharmaceutical Industries Ltd. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 78: Sun Pharmaceutical Industries Ltd. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 79: Sun Pharmaceutical Industries Ltd. Breakdown of Net Sales, By  Region, 2016
Figure 80: Senju Pharmaceutical Co., Ltd. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 81: Senju Pharmaceutical Co., Ltd. Breakdown of Net Sales, By Business Segment, 2016
Figure 82: Johnson & Johnson  Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 83: Johnson & Johnson R&D Expenditure (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 84: Johnson & Johnson Breakdown of Net Sales, By Business Segment, 2016
Figure 85: Otsuka Pharmaceutical Co., Ltd. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 86: Otsuka Pharmaceutical Co., Ltd.  R&D Expenditure (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 87: Otsuka Pharmaceutical Co., Ltd. Breakdown of Net Sales, By Business Segment, 2016

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

835

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved